Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis

Haemodialysis (HD) patients present more morbidity and mortality risk in coronavirus disease 2019 (COVID-19). In patients who may develop severe symptoms, the process called ‘viral sepsis’ seems to be a crucial mechanism. In those cases, the HD procedure provides an excellent tool to explore the ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandoval, Diego, Rama, Inés, Quero, María, Hueso, Miguel, Gómez, Francisco, Cruzado, Josep M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Exceptional Cases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929023/
https://www.ncbi.nlm.nih.gov/pubmed/33953913
http://dx.doi.org/10.1093/ckj/sfab010
Descripción
Sumario:Haemodialysis (HD) patients present more morbidity and mortality risk in coronavirus disease 2019 (COVID-19). In patients who may develop severe symptoms, the process called ‘viral sepsis’ seems to be a crucial mechanism. In those cases, the HD procedure provides an excellent tool to explore the benefit of some extracorporeal therapies. We reported the outcome of four HD patients with severe COVID-19 treated with Seraph(®)100 haemoperfusion (HP) device. Three of the four cases presented a good clinical response after HP. In conclusion, the treatment with Seraph(®)100 device may be a simultaneous treatment to improve HD patients with severe acute respiratory syndrome coronavirus 2.

Ejemplares similares